EU/3/18/2065

About

On 24 August 2018, orphan designation (EU/3/18/2065) was granted by the European Commission to SFL Regulatory Services GmbH, Austria, for obiltoxaximab for the treatment of anthrax.

The sponsorship was transferred to SFL Pharmaceuticals Deutschland GmbH, Germany, in July 2020.

Key facts

Active substance
Obiltoxaximab
Disease / condition
Treatment of anthrax
Date of first decision
24/08/2018
Outcome
Positive
EU designation number
EU/3/18/2065

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

SFL Pharmaceuticals Deutschland GmbH
Marie-Curie-Strasse 8 
79539 Loerrach 
Germany
Tel: +49 7621 5500 250
E-mail: office@sfl-services.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating